Kornimate/medical-research-clean huggingface dataset:
tace with or without sbrt as bridging therapy for pre-transplant hcc patients

Conditions: Hepatocellular Carcinoma

Summary: this trial is designed to be the initial prospective pilot investigation of the effectiveness of combined sbrt and tace as bridging therapy for hcc patients awaiting liver transplanation. no prospective clinical trials regarding the combination of tace and sbrt in pre-transplant population have been performed. we propose the trial be conducted as a pilot clinical trial with the goal of enrolling 40 patients into each arm

the purpose of this study is to determine whether the combination of stereotatic body radiotherapy (sbrt) tand transarterial chemoembolization (tace) is an effective "bridging therapy" for patients hepatocellular carcinoma (hcc) of the liver awaiting transplantation.

Eligibility criteria:
inclusion criteria: * patient capable of giving informed consent * patient diagnosed with hepatocellular carcinoma and listed or recommended to be listed for orthotopic liver transplantation at the participating institution * age \> 18 years old * meets clinical criteria for eligibility for tace to the target lesion per interventional radiology * childs' class a or b7 * eastern clinical oncology group performance status 0 or 1 exclusion criteria: * prior radiotherapy to the upper abdomen or radioembolization of the liver * prior tace to the target lesion, rfa, or liver transplant * active gi bleed within 2 weeks of study enrollment * active gi ulcer disease within 4 weeks of study enrollment * ascites refractory to medical therapy * contraindication to receiving radiotherapy or tace * complete obstruction of portal venous flow to the segment of liver that includes the target lesion * contraindication to both contrast enhanced mri and contrast enhanced ct (i.e. unable to undergo follow-up imaging or sbrt treatment planning) * women who are pregnant * participation in another concurrent treatment protocol
evaluation of a 3d functional metabolic imaging and risk assessment system in classifying women for likelihood of breast cancer

Conditions: Breast Cancer

Summary: the study objective is to evaluate the added value of mira technology as an adjunct to mammography in the detection of malignant breast lesions in women with dense breast and/or at elevated risk of breast cancer.


Eligibility criteria:
inclusion criteria: \*\*calibration phase: a.subjects who are asymptomatic and scheduled to undergo routine screening mammography. or b.subjects scheduled for image guided needle biopsy as a result of findings obtained during standard of care (mammography, ultrasound and/or mri) \*\*testing phase: a. subjects scheduled to undergo routine screening mammography and at least one of the following : * subjects whose most recent (within 3 years) prior mammogram was interpreted as heterogeneously dense (acr bi-rads breast density 3) or extremely dense (acr bi-rads breast density 4). * subjects whose current 10-year ibis breast cancer risk is 5% or higher. exclusion criteria, valid for both calibration and testing phases: 1. male by birth. 2. individual is less than 24 years old. 3. contraindication to bilateral mammography or mri. 4. subjects who are unable to read, understand and execute the informed consent procedure. 5. subjects who have had mammography, ultrasound or mri examination performed on the day of the study prior to mira scan. 6. subjects who have significant existing breast trauma. 7. subjects who have undergone lumpectomy/mastectomy. 8. subjects who have undergone breast reduction or breast augmentation. 9. subjects who have undergone any other type of breast surgery. 10. subjects who have large breast scar / breast deformation. 11. subjects who have undergone a breast needle biopsy within the 6 month period prior to their intended enrollment into the study. 12. subjects who have a temperature \> 100° f (37.8c) degrees on the day of the mira imaging. 13. subjects who are pregnant or lactating. 14. subjects who have had placement of an internal breast marker. 15. subjects with known raynaud's disease. 16. subjects that are claustrophobic or have physical limitations that do allow them to sit in the system chair for the required imaging session. 17. subjects with implanted pacemaker/defibrillator, implanted venous access device (portacath) or other implanted devices. 18. subjects with a bi-rads category 6 (e.g. for which mammogram was performed for the purpose of planning cancer therapy). 19. subjects affected with epilepsy. 20. subjects who participated in the calibration phase will not be able to participate in the testing phase.
determining the prevalence of frailty and evaluating its relationship with mortality.

Conditions: Frailty; Mortality; COVID-19

Summary: covid-19 patients admitted to the intensive care unit of selcuk university hospital were included in the study. clinical frailty score was given during admission to the intensive care unit. demographic data, laboratory data, radiological imaging and vital signs of the patients were recorded. treatment and patient positions were recorded during the intensive care follow-up of the patients. mortality status of the patients 6 months after admission to the icu was recorded.

it is planned to include non-pregnant and non-traumatic patients over the age of 18, diagnosed with covid-19, who are treated in the intensive care unit of selcuk university hospital. the frailty status will be evaluated by using the clinical frailty scale at the admission of the patients to the intensive care unit. evaluation from the patient himself, if the consciousness of the patients is clear; if not, it will be done near the patient. patients will be divided into two groups using the clinical frailty scale (cfs) as frail if the score is ≥5 and non-fragile if the score is \ 10, it will be considered as severe involvement. laboratory values; platelet and lymphocyte count, albumin, sodium, ferritin, d-dimer, crp, procalcitonin, interleukin-6 and glomerular filtration rate values, neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, crp/albumin ratio, arterial blood gas will be recorded. whether or not he received respiratory support; type (invasive/non-invasive positive pressure respiratory support or high-flow nasal oxygen therapy), duration will be recorded. the use and duration of vasoactive drugs administered, renal replacement therapy and its durations will be recorded. patient positions will be recorded as supine, lateral decubitus, and prone. the length of stay in the intensive care unit and mortality of the patients will be recorded. comparisons will be made between frail and non-fragile groups on all these evaluated parameters.

Eligibility criteria:
inclusion criteria: * patients who over the age of 18 * patients who diagnosed with covid-19 exclusion criteria: * trauma patient * pregnant
effectiveness of psychodermatologic educational modules on atopic dermatitis patient outcomes: a randomized controlled trial

Conditions: Atopic Dermatitis (AD)

Summary: in a previous part of this study, we created educational modules about the psychodermatology of inflammatory skin conditions, with a particular emphasis on atopic dermatitis, for patients. these modules will empower patients to better manage both the psychological and physical aspects of their skin conditions. as part of this project, we aim to conduct a clinical trial to determine the effectiveness of these modules on eczema severity and health-related quality of life in patients. we hope to use these findings to develop and disseminate accessible educational material on the psychological aspects of dermatologic care.


Eligibility criteria:
inclusion criteria: 1. new diagnosis or follow-up for previous diagnosis of atopic dermatitis. 2. reliable internet access to be able to access the e-modules. 3. able to speak english at a level required to understand the content of this study. 4. child participants will be included in this study contingent on the consent of their guardian/caregiver(s). 5. age range of eligible participants: age 4 years and older. exclusion criteria: 1. does not have a new diagnosis or follow-up for previous diagnosis of atopic dermatitis. 2. unable to access and/or navigate e-modules with reasonable support/instruction. 3. unable to speak english at a level required to understand the content of this study. 4. unable to provide informed consent. 5. less than 4 years of age.

Keywords: atopic dermatitis dermatology psychodermatology patient education
kinesio taping for balance and function in low back pain

Conditions: Balance Disorders; Low Back Pain

Summary: this study aims to examine the effects of kinesiology taping on balance and functional ability in individuals with nonspecific low back pain. nonspecific low back pain is a common condition that is not linked to a specific medical cause and is often associated with balance problems, reduced physical function, and psychological challenges. in this study, 35 patients aged between 18 and 65 were included. one group received kinesiology taping along with physiotherapy, while the other group received only physiotherapy.

nonspecific low back pain (nslbp) is a common musculoskeletal condition that cannot be attributed to a specific pathology. it often leads to limitations in functional activities, impaired balance, and psychological distress, such as depressive symptoms. this study investigates the effects of kinesiology taping on balance and functional outcomes in individuals diagnosed with nslbp. the study was conducted on 35 participants aged 18 to 65 years. participants were randomly assigned to two groups: the intervention group received kinesiology taping in combination with physiotherapy, while the control group received only physiotherapy treatment. various outcome measures were used to assess the effects of the interventions, including the visual analog scale (vas) for pain intensity, functional rating index (fri), modified oswestry disability index (modi), beck depression inventory (bdi), nottingham health profile (nhp), and the flamingo balance test.

Eligibility criteria:
inclusion criteria: * patients aged between 18 and 65 years * diagnosis of nonspecific low back pain * duration of low back pain longer than 6 weeks * ability to attend an outpatient physiotherapy program exclusion criteria: * history of spinal surgery * presence of neurological deficits on physical examination * contraindication to kinesiology taping * pregnancy * cardiovascular or pulmonary diseases that contraindicate exercise * history of lower extremity surgery

Keywords: kinesiology taping nonspecific low back pain physiotherapy
effect of preservative-free low-dose hyaluronic acid-containing salt solution on dry eye disease

Conditions: Dry Eye

Summary: this trial is a randomized, parallel-group, double-blind, controlled clinical trial to evaluate the effect of hyaluronic acid (ha) on dry eye disease.

this trial is a randomized, parallel-group, double-blind, controlled clinical trial to compare intervention treatment (per-young eye drops: preservative-free 0.15% ha) against control treatment (aim artificial tears: salt solution without 0.15% ha). all participants will be received per-young eye drops (4 to 8 times per day) or aim artificial tears (4 to 8 times per day) with 12 weeks. two drugs are identical in appearance and order of administration will be double-blind randomized. primary endpoint: to compare the central tear meniscus height (tmhc) of treatment with preservative-free 0.15% ha to the treatment with salt solution without 0.15% ha at 4 weeks.

Eligibility criteria:
inclusion criteria: * male or female subjects aged greater than or equal to 20 years (\>= 20 years). * the symptom criterium of ocular surface disease index (osdi) score \> 13. * one of the two following examination criteria: 1. central tear meniscus height (tmhc) \< 0.20 mm, 2. noninvasive tear-break time (nitbut) \< 6 s, for at least one eye. * informed consent form (icf) signed by the participant or a legal guardian. exclusion criteria: * male or female subjects aged less than 20 years (\<20 years). * the symptom criterium of ocular surface disease index (osdi) score \< 13. * central tear meniscus height (tmhc) \> 0.20 mm and noninvasive tear-break time (nitbut) \> 6 s for each eye. * acute inflammatory eye diseases. * receive ocular or eyelid surgeries before 6 months (except cataract surgery). * allergy to ha * pregnancy * conditions judged by the investigator as unsuitable for this trial.

Keywords: hyaluronic acid salt solution dry eye disease ocular surface disease
phrenic identification in the icu

Conditions: Ventilator Lung; Ventilator-Induced Lung Injury; Diaphragm Disease; Phrenic Nerve; Phrenic Nerve Stimulation; Neck Anatomy; Ultrasound

Summary: this will be a prospective observational study where the investigator will scan patients' necks with an ultrasound and look for anatomical landmarks that may help identify the phrenic nerve.

patients under protective mechanical ventilation, an intervention that saves lives, may need sedation and paralyzing agents. however, sedation and paralyzing agents are associated with multiple complications, including diaphragm dysfunction. several strategies have been proposed to reduce diaphram dysfunction. a novel approach is to stimulate the phrenic nerve, either transvenously or transcutaneously. transvenous stimulation requires a catheter, which eventually is associated with increased risk of infection and thrombosis. in this scenario, transcutaneous phrenic nerve pacing is attractive but may be more susceptible to patients' anthropometric measures. the correlation between patients' anthropometric measures and the location of the phrenic has been poorly studied.

Eligibility criteria:
inclusion criteria * age ≥ 18 years * admitted to icu exclusion criteria * patients with a cervical spine collar * patients who refuse to participate in the study
the impact of transcutaneous vagus nerve stimulation on cardiovascular events in patients with acute myocardial infarction

Conditions: Acute Myocardial Infarction (AMI)

Summary: the acute mortality rate of acute myocardial infarction (ami) reduced significantly due to emergency reperfusion and subsequent treatment strategies. however, it remains a major cause of disability and death globally. recent studies have shown that systemic inflammation is associated with infarct size and adverse clinical outcomes after myocardial infarction. therefore, attenuating the inflammatory response may be a therapeutic target for acute coronary syndromes and improve clinical outcomes. preclinical and clinical data indicate that vagus nerve stimulation (vns) plays an important role in reducing the inflammatory burden and improving myocardial ischemia. however, more clinical evidence is needed to elucidate the role of vns in patients with acute myocardial infarction and its impact on cardiovascular events. therefore, this study aims to investigate the effect of vagal nerve modulation intervention through a prospective, randomized controlled clinical research method.


Eligibility criteria:
\*\*inclusion criteria\*\* 1. age between 18 and 80 years old (including 18 and 80 years old). 2. patients with acute myocardial infarction who have undergone revascularization of the culprit vessel within 24 hours of onset. 3. willing to participate in this study and have signed the informed consent form. \*\*exclusion criteria\*\* 1. hemodynamically unstable, with cardiogenic shock, requiring medication to maintain blood pressure and heart rate. 2. baseline systolic blood pressure \<90 mmhg or diastolic blood pressure \<40 mmhg. 3. average heart rate under monitoring \<50 beats per minute. 4. patients with ii or iii degree atrioventricular (av) block or sick sinus syndrome who have not had a permanent pacemaker implanted. 5. baseline (before the use of antiarrhythmic drugs) qtc interval ≥500 ms, pr interval \>280 ms. 6. patients who are participating in other clinical studies. 7. other reasons deemed by the investigator as unsuitable for participation in this study.

Keywords: acute myocardial infarcation inflammation vagus nerve stimulation
observational study of vectibix with chemotherapy for metastatic colorectal cancer patients

Conditions: Wild-type RAS Metastatic Colorectal Cancer

Summary: the primary objective was to describe the pattern of use of panitumumab (vectibix®) in combination with chemotherapy in patients with wild-type rat sarcoma viral oncogene homolog (ras) metastatic colorectal cancer (mcrc): as first-line treatment in combination with folfox or folfiri or second-line treatment in combination with folfiri in patients who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan).


Eligibility criteria:
inclusion criteria * subject is ≥ 18 years of age at date of enrolment * histologically or cytologically confirmed carcinoma of colon or rectum * subject with metastatic carcinoma of colon or rectum * confirmed wild-type ras status of tumour * subjects whose care will be managed primarily by the enrolling physician and/ or all records will be available * tumour assessment (ie, computed tomography \[ct\]/magnetic resonance imaging \[mri\]) within 12 weeks (84 days) prior to first vectibix® infusion. * subjects treated with at least one infusion of vectibix® in combination with chemotherapy a maximum of 84 days before entering study: first-line in combination with folfox (folinic acid, leucovorin, fluorouracil \[5fu\], oxaliplatin) or second-line in combination with folfiri (folinic acid, leucovorin, 5fu, irinotecan) in subjects who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan) for treatment of wild-type ras mcrc per approved prescribing information * subject or subject's legally acceptable representative has provided informed consent (for countries where required per local regulations) * subjects treated with vectibix® in accordance with the current version of the summary of product characteristics (smpc) exclusion criteria * ongoing or planned concurrent participation in any clinical study involving investigational product that has not been approved by the european medicines agency for any indication * ongoing or planned concurrent participation in any clinical study where the dosing of vectibix® is determined by the protocol (participation in clinical trials on an approved drug and observational trials are permitted but these cannot mandate how mcrc should be treated)

Keywords: wild-type ras metastatic colorectal cancer vectibix
prevalence of ir in overweight and obese adolescents

Conditions: Insulin Resistance

Summary: the aim of this study is to determine the prevalence of insulin resistance (ir) among overweight and obese adolescents using homa-ir scores and identify lifestyle risk factors in the ir and non-ir group.


Eligibility criteria:
inclusion criteria: * adolescents of ages ≥ 10-≤18 years, of both sexes who are overweight (bmi \> 85th percentile) or obese (bmi \> 95th percentile). exclusion criteria: * obesity due to secondary causes as cushing disease or hypothyroid patients, and any other patients with chronic illness.
correlation of fecal calprotectin and fecal immunochemical test in determination of endoscopic activity in inflammatory bowel disease patients

Conditions: Inflammatory Bowel Disease

Summary: inflammatory bowel disease (ibd) patients often experience a long disease course with periods of remission and flare-ups. currently, in addition to assessing disease stages based on symptoms, colonoscopy performed by specialized physicians is considered the standard for accurately monitoring disease activity. this procedure allows direct visualization of intestinal lesions. however, colonoscopy is complex, costly, carries the risk of complications, and is not suitable for frequent monitoring. this study aims to explore whether stool tests such as calprotectin and immunochemical tests, which are now standard for assessing disease activity in ibd, correlate with colonoscopy results. it also aims to assess the efficacy of these stool tests in determining whether the disease is in remission or active. the objective of the study is to investigate the correlation and efficacy of stool test results, calprotectin and fecal immunochemical test, compared to colonoscopy in patients with ibd.


Eligibility criteria:
inclusion criteria: * patients aged 18 years or older. * diagnosed with inflammatory bowel disease, either ulcerative colitis or crohn's disease. * scheduled for colonoscopy for various indications, including: 1. follow-up after treatment to assess disease remission 2. clinical symptoms or laboratory results suggesting disease flare, such as increased abdominal pain, more frequent diarrhea, or elevated inflammatory markers in the blood 3. screening for colorectal cancer in patients with long-standing inflammatory bowel disease. exclusion criteria: * patients who decline participation in the research project. incomplete or unsuccessful colonoscopy. * failure to provide stool samples. * patients hospitalized for reasons unrelated to inflammatory bowel disease.

Keywords: ibd inflammatory bowel disease endoscopy fecal calprotectin
a novel appendicitis trimodal prediction score (atmos) for acute appendicitis in pregnancy: a retrospective observational study

Conditions: Appendicitis in Pregnancy

Summary: acute appendicitis (aa) is a disease of younger age, but it occurs in 1 out of 500-2000 pregnancies. the current treatment of choice for aa in pregnancy is surgical. even with standard clinical examination, serum inflammatory markers, and transabdominal ultrasound, the decision on surgical treatment of acute appendicitis (aa) and the rate of negative appendectomy in pregnancy are still unsatisfactory. there are several scoring systems (alvarado, tzanakis) that help making decision on operating more easier, however their specificity is either high with low sensitivity, or the other way around. in addition, all scores are based on adult non-pregnant population. we are making an observational study to develop a scoring system that would include ultrasonic imaging with clinical-biochemical parameters while not compromising sensitivity and specificity.

the study includes extraction of medical data for pregnant women, age 18 years or older, admitted to the university hospital centre zagreb, zagreb, croatia, with the suspicion of aa, from january 2010 to december 2020. the aim of this study is to develop a scoring system that would include ultrasonic imaging with clinical-biochemical parameters while not compromising sensitivity and specificity.

Eligibility criteria:
inclusion criteria: * pregnant women, age 18 years or older, admitted to the university hospital centre zagreb, zagreb, croatia, with the suspicion of acute appendicitis, from january 2010 to december 2020. exclusion criteria: * non-pregnant patients * pregnant patients younger than 18 years * diagnosis made with ct or mri * pregnant patients with the acute abdomen (intraoperative diffuse peritonitis) from acute appendicitis

Keywords: appendicitis, pregnancy, score, ultrasound, neutrophil-lymphocyte ratio, crp-platelet ratio